The program begins on Wednesday, July 1, 2026 and goes until December 31, 2027
This blog, based on IQVIAs 18th March 2026 webinar on the future of the Obesity Medicines market, looks ahead to the next phase of that transformation, examining how the obesity market evolves from 2026 to 2030, and how the drivers of success shift from rapid adoption to differentiation, longterm performance and systemlevel impact
Its so much more than irregular periods and acne (though those are frustrating enough on their own)
Phase 3 trials with longer duration will provide clearer answers
10.1038/s41591-021-01425-3 [DOI] [PubMed] [Google Scholar] 17.Loomba, R
However, when semaglutide is part of the picture, these ratios need some adjustment